Background/Objectives: Datopotamab deruxtecan was approved in 2025 for hormone receptor-positive, HER2-negative metastatic breast cancer and for EGFR-mutated non-small cell lung cancer (NSCLC); its safety profile in routine use has not been described. We characterized adverse event reporting for the agent and asked whe...
Osman Bilge Kaya, B. Karabuğa, E. Aydemir et al.· Pharmaceuticals· 0 citations
Multidrug chemotherapy was associated with lower hazards of progression or death and of death than gemcitabine monotherapy in the primary overlap-weighted analysis and should be interpreted descriptively because of the small sample size, later treatment era, and potential residual confounding.
F. Kuş, F. Atalah, Gökhan Şahin et al.· BMC Cancer· 0 citations
Landmark-based conditional survival analysis provides clinically meaningful, time-updated prognostic information in HR+/HER2- mBC treated with first-line CDK4/6 inhibitors and support the integration of milestone-based conditional survival estimates alongside conventional baseline survival metrics in the CDK4/6i era.
Findings support an individualized, risk-adapted sequencing approach in carefully selected patients but do not establish equivalence or justify routine deferral.
Pınar Kubilay Tolunay, Bediz Kurt İnci, B. Karabuğa et al.· Biomedicines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.